Comparative Pharmacology
Head-to-head clinical analysis: FLO PRED versus KENALOG IN ORABASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLO PRED versus KENALOG IN ORABASE.
FLO-PRED vs KENALOG IN ORABASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, suppress immune response, and inhibit phospholipase A2, decreasing prostaglandin and leukotriene synthesis.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, suppress immune response, and inhibit fibroblast proliferation.
Initial: 5-60 mg orally daily in divided doses; maintenance: 5-15 mg orally daily. Also available as ophthalmic suspension (1 drop 2-4 times daily).
Apply a thin layer to the affected area 2-4 times daily, after meals and at bedtime. Do not rub in; allow to form a film.
None Documented
None Documented
The terminal elimination half-life of prednisolone is approximately 2-4 hours (mean ~3 hours) in adults with normal hepatic function. This short half-life allows for once-daily or alternate-day dosing to minimize adrenal suppression.
Terminal half-life approximately 2-5 hours following mucosal application.
FLO-PRED (prednisolone acetate) is primarily eliminated via hepatic metabolism, with inactive metabolites excreted renally. Approximately 20-30% of a dose is excreted unchanged in urine, and less than 5% is eliminated via biliary/fecal routes.
Primarily hepatic metabolism; metabolites excreted renally (~75%) and in feces (~10%).
Category C
Category C
Corticosteroid
Corticosteroid